Jeremy Grantham's JNJ Position Overview
Jeremy Grantham (via Grantham, Mayo, Van Otterloo & Co. LLC) currently holds 6.82 M shares of Johnson & Johnson (JNJ) worth $1.26 B, representing 3.56% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Jeremy Grantham has maintained a long-term strategic position in JNJ, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2015, adding 1.57 M shares. Largest reduction occurred in Q2 2014, reducing 3.28 M shares.
Analysis based on 13F filings available since 2013 Q2
Jeremy Grantham's Johnson & Johnson (JNJ) Holding Value Over Time
Track share changes against reported price movement
Quarterly Johnson & Johnson (JNJ) Trades by Jeremy Grantham
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +23.17 M | Add 0.00% | 23.17 M | $85.86 |
| Q3 2013 | -1.96 M | Reduce 8.46% | 21.21 M | $86.69 |
| Q4 2013 | -1.43 M | Reduce 6.76% | 19.78 M | $91.59 |
| Q1 2014 | -2.2 M | Reduce 11.13% | 17.57 M | $98.23 |
| Q2 2014 | -3.28 M | Reduce 18.65% | 14.3 M | $104.62 |
| Q3 2014 | -2.16 M | Reduce 15.09% | 12.14 M | $106.59 |
| Q4 2014 | -442,754 | Reduce 3.65% | 11.7 M | $104.57 |
| Q1 2015 | +1.57 M | Add 13.43% | 13.27 M | $100.60 |
| Q2 2015 | -361,700 | Reduce 2.73% | 12.91 M | $97.46 |
| Q3 2015 | -1.38 M | Reduce 10.67% | 11.53 M | $93.35 |
| Q4 2015 | -1.56 M | Reduce 13.52% | 9.97 M | $102.72 |
| Q1 2016 | -934,036 | Reduce 9.37% | 9.04 M | $108.20 |
| Q2 2016 | +705,025 | Add 7.80% | 9.74 M | $121.30 |
| Q3 2016 | -2.46 M | Reduce 25.24% | 7.28 M | $118.13 |
| Q4 2016 | -2.03 M | Reduce 27.84% | 5.26 M | $115.21 |
| Q1 2017 | -335,604 | Reduce 6.39% | 4.92 M | $124.55 |
| Q2 2017 | +130,179 | Add 2.65% | 5.05 M | $132.29 |
| Q3 2017 | -485,071 | Reduce 9.61% | 4.56 M | $130.01 |
| Q4 2017 | -245,619 | Reduce 5.38% | 4.32 M | $139.72 |
| Q1 2018 | +622,584 | Add 14.41% | 4.94 M | $128.15 |
| Q2 2018 | -1.31 M | Reduce 26.60% | 3.63 M | $121.34 |
| Q3 2018 | -993,046 | Reduce 27.38% | 2.63 M | $138.17 |
| Q4 2018 | -188,034 | Reduce 7.14% | 2.45 M | $129.05 |
| Q1 2019 | -179,454 | Reduce 7.34% | 2.27 M | $139.79 |
| Q2 2019 | -108,590 | Reduce 4.79% | 2.16 M | $139.28 |
| Q3 2019 | +65,566 | Add 3.04% | 2.22 M | $129.38 |
| Q4 2019 | +421,607 | Add 18.96% | 2.65 M | $145.87 |
| Q1 2020 | -318,681 | Reduce 12.05% | 2.33 M | $131.13 |
| Q2 2020 | -52,586 | Reduce 2.26% | 2.27 M | $140.63 |
| Q3 2020 | +84,414 | Add 3.71% | 2.36 M | $148.88 |
| Q4 2020 | -24,932 | Reduce 1.06% | 2.33 M | $157.38 |
| Q1 2021 | +11,452 | Add 0.49% | 2.35 M | $164.35 |
| Q2 2021 | +52,426 | Add 2.24% | 2.4 M | $164.74 |
| Q3 2021 | +123,148 | Add 5.14% | 2.52 M | $161.50 |
| Q4 2021 | +34,890 | Add 1.38% | 2.56 M | $171.07 |
| Q1 2022 | +24,261 | Add 0.95% | 2.58 M | $177.23 |
| Q2 2022 | -306,216 | Reduce 11.87% | 2.27 M | $177.51 |
| Q3 2022 | +728,785 | Add 32.05% | 3 M | $163.36 |
| Q4 2022 | -67,804 | Reduce 2.26% | 2.93 M | $176.65 |
| Q1 2023 | +65,324 | Add 2.23% | 3 M | $155.00 |
| Q2 2023 | +362,803 | Add 12.09% | 3.36 M | $165.52 |
| Q3 2023 | +382,035 | Add 11.36% | 3.74 M | $155.75 |
| Q4 2023 | +241,507 | Add 6.45% | 3.99 M | $156.74 |
| Q1 2024 | +841,168 | Add 21.10% | 4.83 M | $158.19 |
| Q2 2024 | +1.2 M | Add 24.79% | 6.02 M | $146.16 |
| Q3 2024 | +269,651 | Add 4.48% | 6.29 M | $162.06 |
| Q4 2024 | +66,206 | Add 1.05% | 6.36 M | $144.62 |
| Q1 2025 | +452,544 | Add 7.12% | 6.81 M | $165.84 |
| Q2 2025 | -258,356 | Reduce 3.79% | 6.55 M | $152.75 |
| Q3 2025 | +260,764 | Add 3.98% | 6.82 M | $185.42 |
Jeremy Grantham's Johnson & Johnson Investment FAQs
Jeremy Grantham first purchased Johnson & Johnson (JNJ) in Q2 2013, acquiring 23,171,691 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham has held Johnson & Johnson (JNJ) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham's largest addition to Johnson & Johnson (JNJ) was in Q2 2013, adding 23,171,691 shares worth $1.99 B. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Jeremy Grantham's firm, Grantham, Mayo, Van Otterloo & Co. LLC, owns 6,815,195 shares of Johnson & Johnson (JNJ), valued at approximately $1.26 B. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Johnson & Johnson (JNJ) represents approximately 3.56% of Jeremy Grantham's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham's peak holding in Johnson & Johnson (JNJ) was 23,171,691 shares, as reported at the end of Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.